Abaloparatide

Drug Profile

Abaloparatide

Alternative Names: Abaloparatide TD; Abaloparatide-SC; BA 058; BA-058-SC; BA-058-TD; BIM-44058; ITM-058; PTHrP; Synthetic human parathyroid hormone 37-70 analogue - Ipsen; TYMLOS

Latest Information Update: 12 Jun 2017

Price : $50

At a glance

  • Originator 3M Drug Delivery Systems; Biomeasure Inc; Ipsen
  • Developer Radius; Radius Health Inc.; Teijin Pharma
  • Class Calcium regulators; Osteoporosis therapies; Peptide hormones
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor type 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Postmenopausal osteoporosis

Highest Development Phases

  • Registered Postmenopausal osteoporosis

Most Recent Events

  • 24 May 2017 Radius Health announces intention to submit sNDA to USFDA for inclusion of data from the ACTIVExtend trial in Postmenopausal osteoporosis
  • 24 May 2017 Updated efficacy data from the phase III ACTIVExtend trial in Postmenopausal osteoporosis released by Radius Health
  • 28 Apr 2017 The label for abaloparatide has a black boxed warning for the risk of osteosarcoma associated with the treatment
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top